Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Parkinson Disease 4 Clear all

Recruiting Phase 3 Interventional

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112

View directory record Official record

Conditions: Endometrial Cancer
Interventions: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 59
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 53 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 2 Interventional Results available

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

NCT03037203

View directory record Official record

Conditions: Excessive Sleepiness, Parkinson Disease
Interventions: JZP-110, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 35 Years to 80 Years

Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more

Source: ClinicalTrials.gov public record

Updated Jan 8, 2020 · Synced May 22, 2026, 12:05 AM EDT

Terminated Phase 1 Interventional Results available

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

NCT03833427

View directory record Official record

Conditions: Advanced/Metastatic Solid Tumors
Interventions: Selumetinib, Pembrolizumab; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more

Source: ClinicalTrials.gov public record

Updated Nov 6, 2024 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

NCT03221426

View directory record Official record

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 14
States / cities: Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more

Source: ClinicalTrials.gov public record

Updated Mar 8, 2026 · Synced May 22, 2026, 12:05 AM EDT

Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

NCT03753243

View directory record Official record

Conditions: Prostate Cancer
Interventions: Pembrolizumab, Enzalutamide; Drug
Lead sponsor: Mark Garzotto, MD; Federal
Eligibility: 18 Years and older · Male only

Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Source: ClinicalTrials.gov public record

Updated Apr 19, 2022 · Synced May 22, 2026, 12:05 AM EDT

Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

NCT03924869

View directory record Official record

Conditions: Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo; Radiation · Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more

Source: ClinicalTrials.gov public record

Updated Dec 10, 2025 · Synced May 22, 2026, 12:05 AM EDT

Recruiting No phase listed Observational

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

NCT07219927

View directory record Official record

Conditions: Parkinson Disease
Interventions: Observational study; Other
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Aliso Viejo, California • Irvine, California • Palo Alto, California + 2 more

Source: ClinicalTrials.gov public record

Updated Oct 21, 2025 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 2 Interventional Results available

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219

View directory record Official record

Conditions: Renal Cell Carcinoma
Interventions: Pembrolizumab, Lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more

Source: ClinicalTrials.gov public record

Updated Dec 2, 2025 · Synced May 22, 2026, 12:05 AM EDT

Active, not recruiting Phase 1Phase 2 Interventional

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

NCT04626479

View directory record Official record

Conditions: Carcinoma, Renal Cell
Interventions: Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Vibostolimab/Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years

Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 6 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866

View directory record Official record

Conditions: Advanced Idiopathic Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 30 Years to 80 Years

Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 6, 2014 · Synced May 22, 2026, 12:05 AM EDT

Terminated Phase 1 Interventional Results available

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

NCT04135352

View directory record Official record

Conditions: Neoplasm Metastasis
Interventions: 200 mg of pembrolizumab, V938; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Houston, Texas • Salt Lake City, Utah

Source: ClinicalTrials.gov public record

Updated Nov 11, 2024 · Synced May 22, 2026, 12:05 AM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523

View directory record Official record

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: AZD2936; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years

Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia

Source: ClinicalTrials.gov public record

Updated Mar 23, 2026 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 2 Interventional Results available

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811

View directory record Official record

Conditions: Sialorrhoea
Interventions: oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D; Drug
Lead sponsor: Orient Pharma Co., Ltd.; Industry
Eligibility: 40 Years to 80 Years

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Bingham Farms, Michigan

Source: ClinicalTrials.gov public record

Updated Apr 9, 2023 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

NCT03066778

View directory record Official record

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more

Source: ClinicalTrials.gov public record

Updated Oct 2, 2022 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 3 Interventional Results available

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552

View directory record Official record

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older

Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 23
States / cities: Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more

Source: ClinicalTrials.gov public record

Updated Sep 13, 2022 · Synced May 22, 2026, 12:05 AM EDT

Recruiting Phase 1Phase 2 Interventional

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944

View directory record Official record

Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more

Source: ClinicalTrials.gov public record

Updated Apr 30, 2026 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 2 Interventional Results available

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151

View directory record Official record

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 55
States / cities: Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more

Source: ClinicalTrials.gov public record

Updated Dec 3, 2025 · Synced May 22, 2026, 12:05 AM EDT

Active, not recruiting Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

NCT04956692

View directory record Official record

Conditions: Non-Small Cell Lung Cancer
Interventions: Pembrolizumab SC, Pembrolizumab IV, Paclitaxel, Nab-Paclitaxel, Carboplatin, Cisplatin, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 18
States / cities: Jonesboro, Arkansas • Fullerton, California • Los Alamitos, California + 14 more

Source: ClinicalTrials.gov public record

Updated Dec 2, 2024 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 3 Interventional Results available

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

NCT04776148

View directory record Official record

Conditions: Colorectal Neoplasms
Interventions: pembrolizumab, lenvatinib, regorafenib, TAS-102 (trifluridine and tipiracil); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Monterey, California • Marietta, Georgia • Chicago, Illinois + 8 more

Source: ClinicalTrials.gov public record

Updated Feb 4, 2026 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 3 Interventional Results available

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

NCT05064059

View directory record Official record

Conditions: Colorectal Cancer
Interventions: favezelimab/pembrolizumab, regorafenib, TAS-102; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more

Source: ClinicalTrials.gov public record

Updated Sep 16, 2025 · Synced May 22, 2026, 12:05 AM EDT

Recruiting Phase 1 Interventional

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189

View directory record Official record

Conditions: Non-Small Cell Lung Cancer
Interventions: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older

Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 5
States / cities: Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 13, 2026 · Synced May 22, 2026, 12:05 AM EDT

Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

NCT07348250

View directory record Official record

Conditions: Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
Interventions: [18F]MK-0947; Drug
Lead sponsor: Invicro; Other
Eligibility: 18 Years to 80 Years

Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated Jan 15, 2026 · Synced May 22, 2026, 12:05 AM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767

View directory record Official record

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND); Biological · Other · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more

Source: ClinicalTrials.gov public record

Updated Jan 12, 2026 · Synced May 22, 2026, 12:05 AM EDT

Completed Phase 1Phase 2 Interventional

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

NCT04303169

View directory record Official record

Conditions: Melanoma
Interventions: Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years

Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more

Source: ClinicalTrials.gov public record

Updated Oct 26, 2025 · Synced May 22, 2026, 12:05 AM EDT